Recent studies in rodents suggest that n-3 long-chain polyunsaturated fatty acids act as peroxisome proliferator-activated receptor-α ligands in improving non-alcoholic fatty liver disease.
However, data in humans are still lacking.
Dr Capanni and colleagues evaluated the efficacy of prolonged polyunsaturated fatty acids supplementation in non-alcoholic fatty liver disease.
The team enrolled 56 patients with non-alcoholic fatty liver disease.
Among the overall eligible patients, 42 received n-3 polyunsaturated fatty acids 1-g capsule daily for 12 months.
However, 14 refused the treatment and were analyzed as controls.
All patients underwent hematochemical and ultrasound follow-up.
| Polyunsaturated fatty acids increased Doppler perfusion index|
|Alimentary Pharmacology & Therapeutics|
The researcher found that polyunsaturated fatty acid supplementation significantly decreased serum aspartate transaminase.
Alanine transaminase, γ-glutamyl transpeptidase, triglycerides, and fasting glucose was also decreased in comparison with controls.
Circulating arachidonate and n-6/n-3 fatty acid ratio was reduced in treated patients.
Moreover, ultrasonography demonstrated improvement of liver echotexture after polyunsaturated fatty acids.
The researchers showed that polyunsaturated fatty acids increased Doppler perfusion index.
However, the team observed no significant changes occurred in controls.
Dr Capanni's team concluded, “Supplementation with n-3 polyunsaturated fatty acids improves biochemical, ultrasonographic and haemodynamic features of liver steatosis.”
“This study supports the efficacy of n-3 polyunsaturated fatty acids as a new therapeutic approach in the treatment of non-alcoholic fatty liver disease.”